What is claimed is:

1. A formulation comprising: from 18% (w/w) to 23% (w/w) CR845.HCl (D-Phe-D-Phe-D-Leu-D-Lys-[ω(4-aminopiperidine-4carboxylic acid)]-OH.HCl), from 60% (w/w) to 77% (w/w) trehalose suspended in an absorption enhancer comprising a medium chain fatty acid glyceride, wherein the medium chain fatty acid is selected from caproic, caprylic and capric acids; wherein the CR845.HCl exhibits a bioavailability of greater than 10%.

2. The formulation according to claim 1, wherein the glyceride of the medium chain fatty acid is a glyceride of caprylic and/or capric fatty acids.

3. The formulation according to claim 1, wherein the glyceride of the medium chain fatty acid is a triglyceride of caprylic and/or capric fatty acids.

4. The formulation according to claim 2, further comprising capric acid.

5. The formulation according to claim 2, further comprising sodium caprate.

6. The formulation according to claim 2, wherein the kappa opioid receptor agonist is embedded in a particle comprising trehalose.

7. The formulation according to claim 2, further comprising a chelating agent, wherein the chelating agent is succinic acid or EDTA.

8. The formulation according to claim 2, wherein the formulation comprises from 25% to 92% (w/w) of a triglyceride of caprylic and/or capric fatty acids.

9. The formulation according to claim 8, comprising from 5% to 20% (w/w) of capric acid.

10. The formulation according to claim 8, comprising from 5% to 20% (w/w) of sodium caprate.

11. A pharmaceutical composition, comprising the formulation according to claim 1 and a pharmaceutically acceptable excipient, diluent or binder.

12. The pharmaceutical composition according to claim 11 in an enterically coated capsule or a capsule having intrinsically enteric properties.

13. A formulation for oral delivery of a kappa opioid receptor agonist, comprising CR845 (D-Phe-D-Phe-D-Leu-D-Lys-[ω(4-aminopiperidine-4carboxylic acid)]-OH) and a glyceride of one or more medium chain fatty acids selected from the group consisting of caproic, caprylic and capric acids, wherein the kappa opioid receptor agonist is embedded in trehalose.

14. The formulation for oral delivery of a kappa opioid receptor agonist according to claim 13, wherein the CR845 (D-Phe-D-Phe-D-Leu-D-Lys-[ω(4-aminopiperidine-4carboxylic acid)]-OH) of the formulation exhibits a stability greater than 96% after storage for a year at 25 ºC.